醣質肝膽磁振造影劑之研究

Abstract

根據衛生署的統計，國人十大死亡原因中，慢性肝病、肝硬化為第六位，而 肝癌更是國內十大癌症死亡原因的第一位，若能早期診斷，應有助於預防肝癌的發 生。新近文獻報導聚合型半乳胺醣胜肽對肝細胞有特異性之結合。本計劃預計建立 可用於診斷肝癌之Gd標誌DTPA 醣質藥物之動物造影技術平台，利用肝癌鼠動 物模式，藉由核磁共振造影結果評估核研Gd-DTPA-lactoside作為肝癌早期診斷的 可行性。

Asialoglycoprotein receptors（ASGP-R）, situated on the hepatocyte membrane, can recognize galactose or N-acetylgalactosamine terminal of desialylated glycoprotein or glycopeptide. Sawamura et al. reported that a decrease in the number of ASGP-R led to an accumulation of asialoglycoprotein in the sera of galactosamine-treated rats, and the number of these receptors decreases in patients with chronic liver diseases. In this study, the hepatoma animal model will be established by treating the animal with proper chemicals. Glyco-drug labeled with Gd will be used to evaluate its potential for diagnosis of liver disease with MRI imaging technique.